Biotech mega-deals boost Pfizer, Sanofi pipelines

Pfizer and Sanofi have each made multi-billion-dollar purchases that widen the scope of their pipelines. Pfizer’s $43 billion acquisition of antibody–drug conjugate (ADC) specialist Seagen gives Pfizer access to Seagen’s linkers, a key part of the technology, and Sanofi’s $2.9 billion buyout of Provention Bio gives Sanofi control of the recently approved Tzield (teplizumab), the first disease-modifying drug for type 1 diabetes (T1D).

Access options

Subscribe to this journal

Receive 12 print issues and online access

214,86 € per year

only 17,91 € per issue

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

About this article

Verify currency and authenticity via CrossMark

Cite this article

Biotech mega-deals boost Pfizer, Sanofi pipelines.
Nat Biotechnol 41, 439 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Read More